Figure 4: Effect of orally administered CuII(atsm) on mitochondrial cytochrome c oxidase and citrate synthase activity in SOD1G93A mice. | Scientific Reports

Figure 4: Effect of orally administered CuII(atsm) on mitochondrial cytochrome c oxidase and citrate synthase activity in SOD1G93A mice.

From: CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord

Figure 4

(A) Cytochrome c oxidase activity in non-transgenic and SOD1G93A mouse spinal cords presented as nmol cytochrome c oxidised min−1 mg−1 tissue protein. (B) Citrate synthase activity in non-transgenic and SOD1G93A mouse spinal cords presented as nmol DTNB reduced min−1 mg−1 tissue protein. Treatments were administered twice daily by gavage and commenced when the mice were 50 days old. CuII(atsm) administered per dose was 50 mg kg−1 mouse body weight. Mice were killed at 120 days old to collect tissues for analysis. Graphed data are box (median ± 95% CI) and whisker (maximum and minimum) plots. No statistically significant differences exist between any of the treatment groups (one-way ANOVA with Tukey’s multiple comparisons test). For all data shown, n = 6 mice per treatment group.

Back to article page